Press release - 10/08/2009 How do immune cells recognise infectious pathogens? Scientists of the University of Heidelberg and the German Cancer Research Centre have clarified the functional principles of an important receptor for bacterial infections: immune cells recognise bacterial and viral pathogens with a receptor known as toll-like receptor 9 (TLR9), which mediates biochemical reaction chains in order to fend off intruders. This discovery made by the Heidelberg researchers paves the way to develop new anti-infective…https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-do-immune-cells-recognise-infectious-pathogens
Peptide-based COVID-19 vaccine - 21/04/2022 CoVac-1: T-cell activator against COVID-19 Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
Article - 28/02/2011 Development of food allergies Allergic reactions to certain types of food can, in extreme cases, lead to life-threatening anaphylactic shock. People with peanut allergies are particularly at risk. Allergic reactions can also gradually develop into chronic intolerances such as coeliac disease, for example. The causes of food allergies nearly always originate in early childhood. https://www.gesundheitsindustrie-bw.de/en/article/news/development-of-food-allergies
The Baden-Württemberg healthcare industry The pharmaceutical industry Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.https://www.gesundheitsindustrie-bw.de/en/location/pharma
Expert interview - 17/10/2018 Biologicals are becoming increasingly important to Boehringer Ingelheim Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
Press release - 24/09/2009 Call for innovative technologies that address global health concerns The World Health Organization is seeking innovative technologies, in particular medical devices that offer solutions to global health concerns in low- and middle-income countries. The deadline for submission of proposals is January the 31st 2010.https://www.gesundheitsindustrie-bw.de/en/article/press-release/call-for-innovative-technologies-that-address-global-health-concerns
Article - 21/11/2011 Johannes Huebner's interest in intestinal bacteria and their sweet-sour capsule Some Enterococcus species are common commensal organisms in human intestines and other species are used in raw-milk cheese where they enhance flavour development. On the negative side enterococci are also a common cause of hospital-acquired infections. Prof. Dr. Johannes Huebner from the Freiburg University Medical Centre is hoping that the bacterias capsular polysaccharides might at some point in the future be used as a vaccine opening the door…https://www.gesundheitsindustrie-bw.de/en/article/news/johannes-huebner-s-interest-in-intestinal-bacteria-and-their-sweet-sour-capsule
Article - 20/10/2014 Michael Schindler: HI virus and host interactions Prof. Dr. Michael Schindler explores the interaction between viruses and their human host cells on the molecular level. His specific interest is HI virus infections and the mechanisms the virus uses to attack the human immune system. Schindler’s eventual aim is to identify a new target for the therapy of HIV infections. In April 2014, Schindler was appointed head of the Department of Molecular Virology of Human Infectious Diseases at the…https://www.gesundheitsindustrie-bw.de/en/article/news/michael-schindler-hi-virus-and-host-interactions
Press release - 16/04/2008 Effective Cancer Immune Therapy Through Order in the Blood Vessels Researchers at the German Cancer Research Center have discovered a key molecule that is responsible for the immature structure of blood vessels in malignant tumors. If this molecule is switched off in mice vessels normalize so that immune cells are better able to get to the tumor tissue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-cancer-immune-therapy-through-order-in-the-blood-vessels
Press release - 30/07/2009 Boehringer Ingelheim set to outpace the market again After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
Article - 27/01/2014 immatics biotechnologies GmbH: active against cancer immatics biotechnologies GmbH is a biopharmaceutical company wholly concerned with the development of advanced immunotherapies that are active against different types of cancer, including renal cell, colorectal, brain and gastric cancer. The company currently has a workforce of 80 at its headquarters in Tübingen and subsidiary in Munich. It capitalises on the know-how in the analysis of tumour cells and vaccine development gained through its…https://www.gesundheitsindustrie-bw.de/en/article/news/immatics-biotechnologies-gmbh-active-against-cancer
Press release - 28/05/2008 Printed biochips In a collaborative project scientists in Stuttgart and Heidelberg succeeded in cutting the production costs for highly complex peptide arrays by a factor of 100 at the same time as being able to increase the number of functional peptides by a factor of 20.https://www.gesundheitsindustrie-bw.de/en/article/press-release/printed-biochips
Article - 20/09/2016 CRISPR-Cas has more surprises in store Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
Press release - 30/10/2017 CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-groundbreaking-of-industrial-scale-gmp-production-facility-for-rna-therapeutics
Press release - 20/08/2021 Innovative Drug Discovery New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation. https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-drug-discovery
Press release - 09/09/2010 China Medical City, Taizhou Taizhou is a commercial and industrial city of around 5 million inhabitants located in the Yantze River Delta about half way between Nanjing and Suzhou. Within the Taizhou city boundaries on a total area of 25 square kilometers China Medical City CMC a national-level pharmaceutical high-tech park is currently under construction. https://www.gesundheitsindustrie-bw.de/en/article/press-release/china-medical-city-taizhou
Funding EU4Health- Programme Funding programme, Funded by: European Union, Submission deadline: 31/12/2027 https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme
Article - 02/05/2016 Biopolymers – raw materials for innovative medical products Polyhydroxyalkanoates (PHA) are biodegradable biopolymers that are becoming increasingly important. Bioplastics are now used not only in everyday objects such as plastic bags and yogurt pots but also increasingly in the field of medicine, which is why intensive research into medical devices made from biodegradable polymers such as PHA has been going on for quite some time. https://www.gesundheitsindustrie-bw.de/en/article/news/biopolymers-raw-materials-for-innovative-medical-products
Article - 12/09/2011 TransLimm brings new immunotherapies to patients more rapidly With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology. https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
Press release - 25/05/2021 From harmless skin bacteria to dreaded pathogens The bacterium Staphylococcus epidermidisis primarily a harmless microbe found on the skin and in the noses of humans. Yet some strains of this species can cause infections – in catheters, artificial joints, heart valves, and in the bloodstream – which are difficult to treat. These bacteria are often resistant to a particularly effective antibiotic, methicillin, and are among the most feared germs in hospitals.https://www.gesundheitsindustrie-bw.de/en/article/press-release/harmless-skin-bacteria-dreaded-pathogens
Press release - 04/02/2010 World Cancer Day: encouraging the prevention, detection and treatment of cancer World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
Dossier - 14/06/2010 Engineers of life Synthetic biology focuses on the development of biological systems with new defined characteristics assembled according to the principles of engineering. Synthetic biology has the potential to be used for a broad range of applications and has solutions in store for major problems of the future. It also fuels fears that human beings are playing the role of creators and going beyond natural boundaries. https://www.gesundheitsindustrie-bw.de/en/article/dossier/engineers-of-life
Article - 19/05/2008 "Fast-track" route to a PhD degree The Chemical Biology graduate school at Constance University was officially opened on 7th May 2008. It was created as part of Germanys excellence initiative and has been training doctoral students since the beginning of April 2008.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fast-track-route-to-a-phd-degree
Article - 29/06/2015 How can influenza virus prediction be improved? Every February, the World Health Organisation (WHO) publishes recommendations on the composition of influenza virus vaccines for use in the upcoming influenza season. The WHO’s decision is based on observations and laboratory tests as well as experience and intuition. The particular type of influenza virus that is likely to be circulating in a given season has previously been mainly a matter of speculation. Richard Neher from the Max Planck…https://www.gesundheitsindustrie-bw.de/en/article/news/how-can-influenza-virus-prediction-be-improved
Press release - 12/10/2009 Immatics appoints Carsten Reinhardt as Chief Medical Officer The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-carsten-reinhardt-as-chief-medical-officer